drugset / Trial / NCT00415194

A Study for Patients With Head and Neck Cancer

NCT00415194

Phase 3 Completed 795 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.

Timeline

Start
2006-12
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous